VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone follows the successful completion of the discovery phase with OmniAb, which delivered a portfolio of therapeutic antibody binders. VERAXA will now focus on engineering the final bispecific ADC candidate and advancing preclinical validation.
The VXA-222 program is not based on VERAXA’s BiTAC platform but leverages the company’s proprietary antibody engineering, linker, and conjugation technologies. It represents one of its more advanced development programs, and its progression underscores VERAXA’s commitment to building a diversified oncology pipeline.
In tandem with this development milestone, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, along with additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
The expansion of the patent portfolio is a strategic move to protect VERAXA’s next-generation antibody technologies, which are central to its pipeline. The company continues to advance its oncology programs, which include bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
The collaboration with OmniAb, which began in May 2025 (https://nnw.fm/nIprz), has been instrumental in identifying promising antibody binders. With the discovery work completed, VERAXA will now combine these binders with its proprietary technologies to build the final therapeutic candidate. This progress is a significant step forward for the VXA-222 program and highlights VERAXA’s ability to execute on its development strategy.
The announcement comes as VERAXA continues to strengthen its position in the oncology space. The company’s focus on innovative antibody-based therapies and its robust intellectual property portfolio position it well for future growth. Investors can stay updated with the latest news and updates relating to VRXA in the company’s newsroom at https://nnw.fm/VRXA.
VERAXA’s advancement of VXA-222 and its expanding patent portfolio demonstrate the company’s dedication to bringing novel cancer therapies to patients. With a diversified pipeline and strong IP protection, VERAXA is poised to make significant contributions to the field of oncology.
